2. Search Result
Search Result
Results for "

CDK2/4/6

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Natural
Products

1

Click Chemistry

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148214
    CDK2/4/6-IN-2

    		CDK Cancer
    CDK2/4/6-IN-2 is a selective CDK2/4/6 inhibitor with IC50 values <1 μM. CDK2/4/6-IN-2 inhibits cells proliferation and phosphorylation of retinoblastoma protein at Ser807/811 in breast cancer cells. CDK2/4/6-IN-2 can be used for the research of cancer, such as breast cancer .
    CDK2/4/6-IN-2
  • HY-148213
    CDK2/4/6-IN-1

    		CDK Cancer
    CDK2/4/6-IN-1(example 29) is a CDK2/4/6 inhibitor with IC50 values of 2.5, 23.7 and 44.3 nM for CDK2, CDK4 and CDK6, respectively. CDK2/4/6-IN-1 can be used in cancer research . CDK2/4/6-IN-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    CDK2/4/6-IN-1
  • HY-N8146
    Bruceantinol

    		STAT Bcl-2 Family Ser/Thr Kinase Survivin c-Myc Apoptosis Necroptosis CDK Infection Cancer
    Bruceantinol is a quassinoid that can be isolated from Brucea javanica, inhibits pepper mottle virus (PepMoV) in pepper. Bruceantinol is a STAT3 inhibitor demonstrating potent antitumor activity in in vitro and in vivo human colorectal cancer (CRC) models. Bruceantinol has potent anti-leukemic activity. Bruceantinol strongly inhibits STAT3 DNA-binding ability (IC50 = 2.4 pM), blocks the constitutive and IL-6-induced STAT3 activation, and suppresses transcription of MCL-1, PTTG1, survivin and c-Myc. Bruceantinol binds with CDK2/4/6 to facilitate protein degradation through proteasome pathway. Bruceantinol can dose- and time-dependently reduces the cell growth, impede cell proliferation, disrupts the cell cycle, and induces necrosis in MCF-7 cells and apoptosis in MDA-MB-231 cells [2] .
    Bruceantinol
  • HY-185121
    PROTAC CDK2/4/6 Degrader-2

    		PROTACs CDK Caspase Cancer
    PROTAC CDK2/4/6 Degrader-2 is a CDK2/4/6 PROTAC degrader. PROTAC CDK2/4/6 Degrader-2. PROTAC CDK2/4/6 Degrader-2 can be converted into the prodrug PROTAC CDK2/4/6 Degrader-1 (HY-171826) through a one-step reaction with chloromethyl pivalate. PROTAC CDK2/4/6 Degrader-2 degrades CDK2/4/6 and their complex in malignant melanomas cells. PROTAC CDK2/4/6 Degrader-2 induces cell cycle arrest and cell apoptosis in various cancer cells, in particular for melanomas. PROTAC CDK2/4/6 Degrader-2 can be used for malignant melanomas research .
    PROTAC CDK2/4/6 Degrader-2
  • HY-171826
    PROTAC CDK2/4/6 Degrader-1

    		CDK PROTACs Cancer
    PROTAC CDK2/4/6 Degrader-1 is an orally active CDK2/CDK4/CDK6 PROTAC degrader. PROTAC CDK2/4/6 Degrader-1 is a prodrug derived from PROTAC CDK2/4/6 Degrader-2 via one-step reaction with chloromethyl pivalate. PROTAC CDK2/4/6 Degrader-1 can be used for malignant melanoma research .
    PROTAC CDK2/4/6 Degrader-1
  • HY-181501
    CDK2/4/6-IN-3

    		Ligands for Target Protein for PROTAC CDK Cancer
    CDK2/4/6-IN-3 (compound 32a) is a CDK2/4/6 inhibitor. CDK2/4/6-IN-3 can be used as a target protein ligand for the synthesis of PROTAC WWZ-11-098 (HY-181490) .
    CDK2/4/6-IN-3
  • HY-132914
    CDK/HDAC-IN-1

    		CDK Cancer
    CDK/HDAC-IN-1 shows remarkable CDK2/4/6 and HDAC6 inhibitory activity of IC50 = 60.9 ± 2.9, 276 ± 22.3, 27.2 ± 4.2, and 128.6 ± 0.4 nM, respectively.
    CDK/HDAC-IN-1
  • HY-172128
    NUAK1-IN-2

    		AMPK CDK Neurological Disease Cancer
    NUAK1-IN-2 (Compound 24) is a NUAK1 (IC50 of 3.162 nM) and CDK2/4/6 inhibitor. NUAK1-IN-2 can be used in cancer, neurodevelopmental disorders and Alzheimer's disease research .
    NUAK1-IN-2
  • HY-181134
    PROTAC HMGCR Degrader-2

    		PROTACs Cancer
    PROTAC HMGCR Degrader-2 is a HMGCR PROTAC degrader with an IC50 value of 0.25 μM. PROTAC degrades HMGCR-2 in Insig-silenced HepG2 cells with a DC50 of 0.12 μM. PROTAC HMGCR Degrader-2 takes PROTAC HMGCR Degrader-1 (HY-171823) as the oral prodrug. PROTAC HMGCR Degrader-2 degrades HMGCR by the VHL-dependent ubiquitin-proteasome system and reduces cellular cholesterol in HepG2 cells. PROTAC CDK2/4/6 Degrader-2 can be used for hyperlipidemia research .
    PROTAC HMGCR Degrader-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: